Skip to main content
QUIT logo

QUIT · Achieve Life Sciences, Inc.

Track QUIT — free
$5.73 -0.15 (-2.47%)
Market Cap
$645.90M
Shares
110.03M
Volume · Nov 20 693.7K Avg daily vol (3M) 1.37M

Price & Indicators

 

Key stats

Close
$5.87
Thu 19 Nov
Open
$5.92
Thu 19 Nov
Average volume, 30 days
1.2M
shares a session
Day range
$5.61$5.99
Open $5.92 Close $5.87
52-week closing range
$2.65$8.53
Close $5.87 31.2% under the high
Short volume, last session
64%
Last earnings
Aug 11, 2026
Latest filing
10-Q · Nov 10
Price history
Jan 2020 to Nov 2026

Latest documents

2026
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
FDA Complete Response Letter cites cytisinicline manufacturing and labeling issues

Achieve Life Sciences received an FDA Complete Response Letter for cytisinicline citing manufacturing and labeling issues. It plans to resubmit in the fourth quarter of 2026 and anticipates potential approval by the end of the second quarter of 2027.

Net loss $12.11M Diluted EPS -$0.11
Read from the MD&A section
3 source passages
In June 2026, we received a Complete Response Letter, or CRL, from the FDA regarding our NDA for cytisinicline relating to outstanding manufacturing-related observations from a current Good Manufacturing Practice, or cGMP, inspection of a third-party manufacturing facility and to final product labeling that was not completed by the FDA’s action date. We intend to resubmit the NDA naming Adare as our finished drug product manufacturer for commercial supply in the fourth quarter of 2026 and anticipate the potential approval of cytisinicline for smoking cessation by the end of the second quarter of 2027, followed by U.S. commercial launch. Achieve is party to the Sopharma Supply Agreement with Sopharma AD, or Sopharma. Open the document at this passage
Nov 10
Current report 8-K
Cash reaches $201.5 million; NDA resubmission on track

AchieveRx reported cash, cash equivalents, and marketable securities of $201.5 million as of September 30, 2026. Cytisinicline’s NDA resubmission remains on track for the fourth quarter of 2026; third-quarter net loss was $12.1 million.

Financial results
4 source passages
Cash, cash equivalents, and marketable securities of $201.5 million as of September 30, 2026 Resubmission of the New Drug Application (NDA) remains on track for the fourth quarter of 2026 Total net loss for the three and nine months ended September 30, 2026, were $12.1 million and $97.0 million, respectively. Achieve Life Sciences, Inc., doing business as AchieveRx (AchieveRx or the Company) (Nasdaq: QUIT) Open the document at this passage
Oct 1
Current report 8-K
Director or officer change, or executive pay

Achieve Life Sciences, Inc. appointed Benjamin Halladay as Chief Financial Officer and principal financial officer effective as of October 5, 2026, while Mark Oki stepped down from the same role effective as of October 5, 2026.

Aug 14
Current report 8-K
Other events AI summary on its way
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$111.71M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$201.52M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+106.7%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Strong Sentiment Bullish Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg +2%
above
Price vs 50-day avg −16%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 55%
mid-range
Momentum
relative strength
Strong
1-month return −10%
trailing
6-month return +11%
trailing
YTD return +18%
this year
Relative strength +16%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow Accumulating
+19% holders QoQ · +34 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
No short-interest data
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
133 holders — near 3-yr high, broad support
Fundamentals
Poor
EPS growth −1%
Y/Y
Free cash flow $-49.5M
Quant / Vol
risk profile
Very High
Volatility 81%
annualized · 1-yr
Max drawdown −55%
past year
ATR 6.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+2% Bullish
Price vs 50-day avg
−16% Bearish
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
55% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow Accumulating
+19% holders QoQ · +34 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
No short-interest data
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
133 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $6 · 55% Range high $9
vs 200-day avg +2% vs 50-day avg -16%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents, and marketable securities $201.5M as of September 30, 2026 —
Quit rate (four-week continuous abstinence), Weeks 49–52 31.2% Weeks 49–52 of ORCA-OL trial —
Quit rate (four-week continuous abstinence), Weeks 9–12 25.5% Weeks 9–12 of ORCA-OL trial —
Quit rate among participants new to cytisinicline at end of treatment 39.4% End of treatment, ORCA-OL trial —
Quit rate among participants who had taken cytisinicline in a prior trial at end of treatment 27.8% End of treatment, ORCA-OL trial —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
QUIT
Achieve Life Sciences, Inc.
this stock
$645.90M +18.1% — — —
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
133
% held
89.0%
Net QoQ
+15.4M sh
Top holder
Frazier Life Sciences Man…
Held Float
View
Short & Settlement
Short Volume
Short vol %
64%
As of
Nov 19, 2026
Short Total
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-54.6M
EPS diluted
$-1.25
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 10, 2026
This year
19

AchieveRx reported cash, cash equivalents, and marketable securities of $201.5 million as of September 30, 2026. Cytisinicline’s NDA resubmission remains on track for the fourth quarter of 2026; third-quarter net loss was $12.1 million.

View
Proposed Sales
Value
$155.1K
Shares
20.6K
Filed
Aug 19, 2026
View
Exempt Offerings
Offering
$25.0M
Filed
Dec 8, 2022
View
Earnings & Events
Webcasts
Last webcast
Aug 11, 2026
View
Investor Relations
Latest news
AchieveRx Reports Third Quarter 2…
Published
Nov 10, 2026
View

Performance

5D 20D 120D MTD YTD
QUIT -6.7% -9.7% +10.8% -14.1% +18.1%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -1.2% -3.4% +16.4% -8.8% +13.1%
Key facts CIK 949858 13F (30d) 142 filings 123 filers Visit website Investor relations